Fournier gangrene: new safety concern of SGLT2 inhibitors

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2019年 / 1753卷 / 1期
关键词：
D O I：
10.1007/s40278-019-61900-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：8 / 8
相关论文
共 50 条
  • [1] Risk of Fournier's gangrene with SGLT2 inhibitors
    Reactions Weekly, 2019, 1738 (1) : 3 - 3
  • [2] FAERS analysis: Fournier gangrene with SGLT2 inhibitors
    Reactions Weekly, 2019, 1754 (1) : 8 - 8
  • [3] Fournier's gangrene and SGLT2 inhibitors: A case study
    Garcia-Garcia, Alejandra
    Galeano-Valle, Francisco
    Antonio Nuevo-Gonzalez, Jose
    Pablo Demelo-Rodriguez, Y.
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2020, 67 (06): : 423 - 425
  • [4] SGLT2 Inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
    Tongtong Wang
    Shrita M. Patel
    Anne Hickman
    Xinyue Liu
    Philip LStJ Jones
    Ira Gantz
    Carol E. Koro
    Diabetes Therapy, 2020, 11 : 711 - 723
  • [5] SGLT2 Inhibitors and the Risk of Hospitalization for Fournier's Gangrene: A Nested Case-Control Study
    Wang, Tongtong
    Patel, Shrita M.
    Hickman, Anne
    Liu, Xinyue
    Jones, Philip L. St J.
    Gantz, Ira
    Koro, Carol E.
    DIABETES THERAPY, 2020, 11 (03) : 711 - 723
  • [6] Fournier gangrene with SGLT-2 inhibitors: administrative claims
    Reactions Weekly, 2019, 1771 (1) : 11 - 11
  • [7] SGLT2 Inhibitors and Ketoacidosis: Cause for Concern?
    Abate, Nicola
    Chandalia, Manisha
    METABOLIC SYNDROME AND RELATED DISORDERS, 2016, 14 (01) : 1 - 2
  • [8] Cardiovascular safety of SGLT2 inhibitors
    Gumprecht, Janusz
    CLINICAL DIABETOLOGY, 2016, 5 (02): : 62 - 65
  • [9] An update on the safety of SGLT2 inhibitors
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (04) : 295 - 311
  • [10] SGLT2 inhibitors and diabetic ketoacidosis — a growing concern
    Guillermo E. Umpierrez
    Nature Reviews Endocrinology, 2017, 13 : 441 - 442
12345